Semaglutide study To determine the therapeutic potential of GLP-1RA on body composition, food intake, and glucose tolerance, we subcutaneously injected mature animals (1830 weeks old) with either vehicle (6% vol/vol DMSO in 0.9% saline) or semaglutide (0.15 mg/kg body weight
Lifestyle interventions remain essential
Because of the retrospective nature of the study and the use of de-identified data, this study received an exemption waiver for approval and informed consent from the Institutional Review Board (IRB) of Chung Shan Medical University Hospital, identified by the reference number CS1-24047
Usually not
Incorporate Natural DPP-4 Inhibitors The Science: While boosting GLP-1 production is important, protecting it from rapid degradation is equally crucial
But its still important to confirm that dual agonist drugs like tirzepatide can offer similar or even potentially greater cardiovascular benefits (in theory, it was possible that one of the ingredients could have negatively affected the heart)